If tumour genetic testing was performed, the panellists considered further germline testing appropriate in patients with high-volume mHSPC (CHAARTED criteria) having a BRCA1/2 tumour (L)PV or a non-BRCA1/2 tumour (L)PV (eg, ATM, CHEK2; Supplementary material). The gene discussed is CHEK2; the disease is neoplasm.